Answers are grounded in this paper and cite their sources.
Donor-derived cellular therapies play a pivotal role in optimizing outcomes after allogeneic hematopoietic stem-cell transplantation (HCT). This article reviews three key post-transplant interventions: donor lymphocyte infusion (DLI), hematopoietic stem-cell boost, and mesenchymal stromal cell (MSC) infusion. DLI remains a cornerstone strategy for enhancing graft-versus-leukemia effects, preventing or treating relapse, and promoting immune reconstitution, while also carrying risk of graft-versus-host disease. Stem-cell boosts, typically performed using CD34⁺ selected products, offer an effective approach for managing poor graft function or mixed chimerism without significantly increasing alloimmune toxicity. MSC infusion has emerged as a promising immunomodulatory therapy for steroidrefractory graft-versus-host disease and for facilitating engraftment, owing to its anti-inflammatory and tissueregenerative properties.
No takes yet. Share an insight, caveat, or question.
Sousa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: